Marksans Pharma Q1 FY27 Results Analysis: EBITDA Margin Expands 919 bps, Revenue Surges 35.6% YoY
Marksans Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 8,407.96 Cr (+35.61% YoY) and PAT growth of +173.89% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 12, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 8,407.96 Cr (+35.61% YoY) |
| PAT (Q1) | Rs. 1,594.07 Cr (+173.89% YoY) |
| EBITDA margin | 25.34% (+919 bps YoY) |
| EPS (Q1) | Rs. 3.47 (+168.99% YoY) |
| Market cap | Rs. 14,168.44 Cr |
| CMP | Rs. 312.60 |
Quarter Snapshot
Marksans Pharma delivered 35.6% YoY revenue growth and a 919 bps EBITDA margin expansion to 25.34%, well above the FY27 guidance of 20-21%. The beat was driven by operating leverage and cost management, though standalone revenue was flat, and the consolidated growth relied heavily on subsidiaries.
Key Investment Insights
Key Positives
- Revenue grew 35.6% YoY to Rs.8,407.96 Cr.
- EBITDA margin expanded 919 bps YoY to 25.34%, above management's FY27 guidance of 20-21%.
- PAT grew 173.9% YoY to Rs.1,594.07 Cr.
- All major cost lines declined as a percentage of revenue YoY.
- Standalone EBITDA margin improved to 25.56% from 21.91% a year ago.
Risk Factors
- Standalone revenue was virtually flat YoY at +0.45%, indicating consolidated growth is primarily driven by subsidiaries.
- Elevated other income (Rs.254.04 Cr) was not itemized; its sustainability is uncertain.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.